Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.44 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in adipocytes | 0.75 |
| chemistry Open Targets | reachable by antibody: ang1005 | 0.45 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 33 Parkinson's papers of 2,191 | 0.54 |
| pathways Reactome | 2 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 0436
Sealed predictions
- LRP1 in dopamine neurons, braak-0.73 (p 0.026) → -0.70 (p 0.035)held
- LRP1 in oligodendrocytes, braak-0.77 (p 0.015) → +0.07 (p 0.855)receipt 0444
Swarm cases
receipt 0444: LRP1 in oligodendrocytes, braak
- power
- full sample -0.51 (p 0.031, n 18), 95% CI -0.79 to -0.06. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.49 (p 0.037, n 18). holds up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.71 (p 0.0011, n 18). not the mix.
- skeptic
- leave-one-out range -0.59 to -0.45, sign flips 0; without severely affected donors -0.51 (p 0.031, n 18). robust.
- cell type
- strongest in dopamine neurons: -0.74 (p 5.0e-4, n 18) vs -0.51 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LRP1 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up LRP1 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 0.0017)
Receipts
loading the receipts